Pure Global AI
jRCT1030230268Recruiting

Untitled Trial

Influence of dosing interval on immune related adverse events and infusion reaction of nivolumab and pembrolizumab
Japan Registry Clinical Trial
VerifiedJapan Registry Clinical Trial
Study focus
Disease/Condition
Neoplasms
Study type
Observational
Sponsor & location
Timeline & enrollment
Phase
N/A
Start date
N/A
End date
N/A
ICD-10 classifications
NeoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasmsMalignant neoplasms
Data source
Registry
Japan Registry Clinical Trial
Trial ID
jRCT1030230268
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for jRCT1030230268 through Pure Global AI's free database. This phase not specified trial is sponsored by sponsor not specified and is currently Recruiting. The study focuses on Neoplasms.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.